Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160003/S026

PRO-Kinetic Energy Coronary Stent System

Biotronik AG · Decision date Apr 1, 2026

FDA DECISIONP160003/S026

What did the FDA decide?

FDA records P160003/S026 as a supplement to PMA P160003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 1, 2026.

FDA approval order statement

the addition of a third pickling line at the stent manufacturing site
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160003/S026
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
MAF
Decision code
OK30
Decision date
Apr 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, CORONARY.

Applicant
Biotronik AG
Product code
MAF
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160003/S026 received

    Application receipt date recorded by FDA.

  2. P160003/S026 · FDA decision

    30-Day Notice

  3. P160003/S022 · Related supplement

    PRO-Kinetic Energy Coronary Stent System

  4. P160003/S024 · Related supplement

    PRO-Kinetic Energy Coronary Stent System

Timeline entries are records held by MedtechLedger for P160003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160003

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA supplementApr 15, 2026FDA
Biotronik AGPMA supplementJun 5, 2026FDA

Explore the linked device profile

Other records with product code MAF

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMar 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records